Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients with Untreated Acute Promyelocytic Leukemia

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

S Mantha;DA Goldman;SM Devlin;J Lee;D Zannino;M Collins;D Douer;HJ Iland;MR Litzow;EM Stein;F Appelbaum;RA Larson;R Stone;B Powell;S Geyer;K Laumann;JM Rowe;H Erba;S Coutre;M Othus;J Park;PH Wiernik;M Tallman Blood Mar 30;129(13):1763-1767

PMid: PMID28082441 | PMC number: PMC5374291

Mutations in Acute Promyelocytic Leukemia are Similar at Diagnosis and Relapse and ETV6 may be a Molecular Biomarker of Decreased Disease Free Survival and High Risk Disease Independent of White Blood Count

E Stein;A Viny;S Devlin;E Paietta;F Appelbaum;J Lancet;R Larson;B Powell;P Wiernik;R Levine;M Tallman International Symposium on Acute Promyelocytic Leukemia (September 24-27, 2017, Rome, Italy), oral presentation

Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia (http://www.bloodjournal.org/content/124/21/2375)

M Baljevic;B Dumitriu;J-W Lee;E Paietta;J Racevskis;C Chen;E Stein;RE Gallagher;JM Rowe;F Appelbaum;B Powell;RA Larson;NS Young;M Tallman Blood 124(21):2375; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

X Poire;BK Moser;R Gallagher;K Laumann;C Bloomfield;B Powell;G Koval;K Gulati;N Holowka;R Larson;M Tallman;F Appelbaum;D Sher;CL Willman;E Paietta;W Stock Leukemia & Lymphoma 55(7):1523-1532

PMid: PMID24160850 | PMC number: PMC4273565

Treatment influenced associations of PML-RARa mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia [PMID22734072]

RE Gallagher;BK Moser;J Racevskis;X Poire;CD Bloomfield;AJ Carroll;RP Ketterling;D Roulston;E Schachter-Tokarz;DC Zhou;D Chen;R Harvey;J Koval;D Sher;JH Feusner;M Tallman;RA Larson;B Powell;F Appelbaum;E Paietta;CL Willman;W Stock Blood 120(10):2098-2108

PMid: PMID22734072 | PMC number: PMC3437597

Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710 [PMID20705755; PMC2981533]

BL Powell;B Moser;W Stock;W Gallagher;C Willman;RM Stone;JM Rowe;S Coutre;JH Feusner;J Gregory;S Couban;FR Appelbaum;MS Tallman;RA Larson Blood 116(10):3751-3757

Clonal markers in relapsed acute promyelocytic leukemia (APL): clinicopathological associations and relation to all-trans retinoic acid (ATRA) treatment on intergroup phase III trial C9710

R Gallagher;B Moser;J Racevskis;X Poire;C Bloomfield;A Carroll;R Ketterling;D Ralston;E Schachter-Tokarz;D Zhou;I-M Chen;R Harvey;G Koval;D Sher;J Feusner;M Tallman;F Appelbaum;R Larson;B Powell;E Paietta;C Willman;W Stock Blood 116:abst.#1038, 2010; American Society of Hematology Annual Mtg, poster

Arsenic trioxide consolidation improves event-free and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup protocol C9710

BL Powell;B Moser;W Stock;RE Gallagher;CL Willman;RM Stone;JM Rowe;SE Coutre;JH Feusner;J Gregory;S Couban;FR Appelbaum;MS Tallman;RA Larson Annals of Hematology 87(Suppl. 1):S77-S78

Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710

BL Powell;B Moser;W Stock;RE Gallagher;C Willman;S Coutre;JH Feusner;FR Appelbaum;MS Tallman;RA Larson Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#2

Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710

W Stock;B Moser;BL Powell;FR Appelbaum;MS Tallman;RA Larson;JH Feusner;CD Bloomfield;C Willman;RE Gallagher Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7016

Relapse of acute promyelocytic leukemia with PML-RARa mutant subclones independent of proximate all-trans retinoic acid selection pressure

RE Gallagher;EL Schachter-Tokarz;DC Zhou;W Ding;SH Kim;BJ Sankoorikal;W Bi;KL Livak;JL Slack;CL Willman Leukemia 20:556-562

Frequent PML-RARa mutations in relapse patients on acute promyelocytic leukemia (APL) intergroup Phase III trial C9710

RE Gallagher;EL Schachter-Tokarz;BK Moser;D Sher;E Paietta;MS Tallman;C Bloomfield;B Powell;RA Larson;FR Appelbaum;CL Willman;RC Harvey Blood 108:#2342